<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nippon Kayaku Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/nippon-kayaku-co-ltd</link>
    <description>Latest news and press releases for Nippon Kayaku Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 23 Mar 2026 12:34:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nippon-kayaku-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d61f52beedb30cb6fc1c9e.webp</url>
      <title>Nippon Kayaku Co., Ltd.</title>
      <link>https://6ix.com/company/nippon-kayaku-co-ltd</link>
    </image>
    <item>
      <title>GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC</title>
      <link>https://6ix.com/company/nippon-kayaku-co-ltd/news/glyconex-inc-and-nippon-kayaku-co-ltd-enter-collaboration-to-advance-next-generation-adc-candidate-gnx201-adc</link>
      <guid isPermaLink="true">https://6ix.com/company/nippon-kayaku-co-ltd/news/glyconex-inc-and-nippon-kayaku-co-ltd-enter-collaboration-to-advance-next-generation-adc-candidate-gnx201-adc</guid>
      <pubDate>Mon, 23 Mar 2026 12:34:00 GMT</pubDate>
      <description>GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. (&quot;Nippon Kayaku&quot;) to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Under the agreement, the two companies will jointly support preclinical development activities for GNX201-</description>
    </item>
  </channel>
</rss>